J&J to file 10 new key drugs by 2019
pharmafile | May 21, 2015 | News story | Sales and Marketing | J&J, JJ
Johnson & Johnson says it plans to file 10 new products with regulators between 2015 and 2019 with each having the potential to exceed $1 billion in revenue.
The US pharma giant also has more than 40 line extensions of existing and new medicines up its sleeve it says, and points to the recent track record of its pharma unit Janssen that has launched 14 drugs since 2009 (half of which are predicted to earn ‘blockbuster’ sales).
“The future of healthcare lies in not only treating disease but also preventing and intercepting diseases before illness occurs,” says William Hait, Janssen’s head of R&D.
“Using our powerful research platforms in combination with our five focussed therapeutic areas, underpinned by strong in-house capabilities and cutting-edge external partnerships, we are striving to deliver the next generation of medical innovations that prevent, intercept and treat disease.”
It lists those five areas as being immunology, infectious diseases and vaccines, neuroscience, cardiovascular and metabolism – and oncology.
In terms of the products behind its growth expectations over the coming years (following any regulatory approval), these include daratumumab for multiple myeloma; sirukumab for rheumatoid arthritis; guselkumab for psoriasis; JNJ-927 (ARN-509) for pre-metastatic prostate cancer; imetelstat for myelofibrosis; JNJ-493 (FGFRi kinase inhibitor) for urothelial cancer.
Then there’s esketamine for treatment-resistant depression; AL-8176 for respiratory syncytial virus (RSV); fulranumab for osteoarthritic pain; JNJ-872 (VX-787) for influenza A; JNJ-922 (Orexin-2 antagonist) for primary insomnia; and AL-335 for hepatitis C.
“In the past two years, our performance and growth rates have been industry-leading, and we look forward to continuing to drive above-industry growth with our current in-market portfolio and next wave of medicines,” says Joaquin Duato, chairman of pharmaceuticals at J&J.
Just this week Janssen also confirmed it is to partner with Achillion Pharmaceuticals to develop and sell new hepatitis C treatments, another lucrative market that is largely dominated by Gilead and AbbVie offerings currently.
Brett Wells
Related Content
J&J seek approval for first drug to treat high-risk smoldering myeloma
Earlier in November, Johnson & Johnson innovative medicine have applied to the US Food and …
European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission …
J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression
Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application …
